15.54

4.90% -0.80

After Hours: 15.60 0.06 +0.39%

Wave Life Sciences Ltd (WVE)

Overview News Price History Option Chain Financials Why WVE Down? Discussions Forecast

Wave Life Sciences Ltd stock is traded at $15.54, with a volume of 3.54M. It is down -4.90% in the last 24 hours and up +118.57% over the past month. WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Previous Close:

$16.34

Open:

$16.35

24h Volume:

3.54M

Relative Volume:

0.59

Market Cap:

$2.89B

Revenue:

$93.95M

Net Income/Loss:

$-129.87M

P/E Ratio:

-17.27

EPS:

-0.9

Net Cash Flow:

$-202.88M

1W Performance:

-7.22%

1M Performance:

+118.57%

6M Performance:

+125.22%

1Y Performance:

+18.72%

1-Day Range:

$15.23

$16.64

1-Week Range:

$15.23

$17.77

52-Week Range:

$5.28

$21.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name

Wave Life Sciences Ltd

Sector

Healthcare (1134)

Industry

Biotechnology (632)

Phone

617-949-2900

Address

7 STRAITS VIEW, SINGAPORE

Employee

288

Twitter

@WAVELifeSci

Next Earnings Date

2025-03-04

Latest SEC Filings

WVE's Discussions on Twitter

Compare WVE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
WVE Wave Life Sciences Ltd	15.54	3.04B	93.95M	-129.87M	-202.88M	-0.90
VRTX Vertex Pharmaceuticals Inc	447.38	114.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	748.71	78.80B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	396.04	51.80B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	847.05	53.08B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	166.55	42.33B	447.02M	-1.18B	-906.14M	-6.1812

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-25	Reiterated	Wedbush	Outperform
Dec-09-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-20-25	Initiated	Wells Fargo	Overweight
Aug-04-25	Initiated	Canaccord Genuity	Buy
Jul-28-25	Initiated	Oppenheimer	Outperform
Jul-16-25	Initiated	Citigroup	Buy
Jun-11-25	Resumed	Raymond James	Outperform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Wedbush	Outperform
Feb-25-25	Initiated	Jefferies	Buy
Oct-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Sep-27-24	Resumed	JP Morgan	Overweight
Sep-19-24	Initiated	B. Riley Securities	Buy
Sep-09-24	Initiated	JP Morgan	Overweight
May-15-24	Initiated	Wells Fargo	Overweight
Dec-19-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Raymond James	Outperform
May-24-23	Downgrade	Jefferies	Buy → Hold
Dec-15-20	Resumed	H.C. Wainwright	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-01-19	Initiated	Guggenheim	Buy
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy
Aug-07-18	Initiated	Stifel	Buy
Jul-23-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Reiterated	Mizuho	Buy
Feb-15-17	Initiated	H.C. Wainwright	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Dec-07-15	Initiated	JMP Securities	Mkt Outperform
Dec-07-15	Initiated	Jefferies	Buy
Dec-07-15	Initiated	Leerink Partners	Outperform
Dec-07-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Wave Life Sciences Ltd Stock (WVE) Latest News

02:57 AM

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data - ts2.tech

02:57 AM

12:38 PM

WAVE Life Sciences (NASDAQ:WVE) Shares Down 4.3%Here's Why - MarketBeat

12:38 PM

Dec 17, 2025

CEO Moves: Is Wave Life Sciences Ltd stock supported by innovation pipeline2025 Market Trends & Step-by-Step Trade Execution Guides - moha.gov.vn

Dec 17, 2025

Wave Life Sciences (WVE) Is Down 19.2% After $350 Million Equity Raise On Obesity DataWhat's Changed - simplywall.st

Dec 17, 2025

Wave Life Sciences drops after trial data for GSK-partnered RNA-editing therapy - MSN

Dec 17, 2025

Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - AOL.com

Dec 17, 2025

United StatesMintz Advises On Wave Life Sciences $402.5 Million Public Offering - Mondaq

Dec 17, 2025

Dec 16, 2025

Oppenheimer Maintains Wave Life Sciences (WVE) Outperform Recommendation - Nasdaq

Dec 16, 2025

Oppenheimer raises WAVE Life Sciences stock price target to $32 on WVE-007 data By Investing.com - Investing.com South Africa

Dec 16, 2025

Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat

Dec 16, 2025

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up Following Insider Buying Activity - MarketBeat

Dec 16, 2025

Oppenheimer Raises Price Target for WAVE Life Sciences (WVE) | WVE Stock News - GuruFocus

Dec 16, 2025

Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility - ts2.tech

Dec 16, 2025

Wave Life (WVE) shares nearly triple on encouraging obesity drug trial - MSN

Dec 16, 2025

Subdued Growth No Barrier To Wave Life Sciences Ltd. (NASDAQ:WVE) With Shares Advancing 128% - simplywall.st

Dec 16, 2025

Oppenheimer raises WAVE Life Sciences stock price target to $32 on WVE-007 data - Investing.com India

Dec 16, 2025

Dec 15, 2025

Obesity data, Kymera and FDA sentiment survey results — a BioCentury podcast - BioCentury

Dec 15, 2025

WAVE Life Sciences (NASDAQ:WVE) Major Shareholder Purchases 1,470,000 Shares - MarketBeat

Dec 15, 2025

Wave Life Sciences’ Obesity Drug Draws $10 Billion Expectations - Finimize

Dec 15, 2025

Wave Life Sciences' Obesity Drug Shows Promise for Long-Term Growth, Truist Says - marketscreener.com

Dec 15, 2025

Truist Securities Maintains Wave Life Sciences (WVE) Buy Recommendation - Nasdaq

Dec 15, 2025

Truist Securities Elevates WAVE Life Sciences (WVE) Price Target to $50 | WVE Stock News - GuruFocus

Dec 15, 2025

WAVE Life Sciences stock price target raised to $50 from $36 at Truist - Investing.com India

Dec 15, 2025

Truist Raises Price Target on Wave Life Sciences to $50 From $36, Keeps Buy Rating - marketscreener.com

Dec 15, 2025

Why Did Wave Life Sciences Surge 147%? - Forbes

Dec 15, 2025

Dec 14, 2025

Wave Life (WVE) Shares Nearly Triple on Encouraging Obesity Drug Trial - Insider Monkey

Dec 14, 2025

Medical Stocks To Watch TodayDecember 8th - MarketBeat

Dec 14, 2025

Dec 13, 2025